Biologic Medicines, Production & Delivery

Own the chain from biologic drug development to bioprocessing and injectable-drug delivery, rather than a general pharmaceutical or biotech momentum basket. Lilly's latest GLP-1 milestone highlights the commercial importance of scalable manufacturing and convenient administration. The basket pairs medicine developers with production-tool and delivery-device businesses; capacity execution and clinical setbacks remain key risks. Catalysts: - 2026-10-15 LLY: GLP-1s took Eli Lilly to a $1 trillion market cap; CEO Dave Ricks is betting billions on further pipeline development (https://www.forbes.com/sites/amyfeldman/2026/10/15/glp-1s-took-eli-lilly-to-1-trillion-ceo-dave-ricks-is-betting-billions-he-can-do-it-again/) Launch basket (equal weight): LLY, TMO, DHR, AMGN, MRNA, NVO, REGN, BMY, RPRX, DXCM Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.